SELECTED PUBLICATIONS
Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement
Strati P, Tang G, Duose DY, Mallampati S, Luthra R, Patel KP, Hussaini M, Mirza AS, Komrokji RS, Oh S, Mascarenhas J, Najfeld V, Subbiah V, Kantarjian H, Garcia-Manero G, Verstovsek S, Daver N
Leuk Lymphoma 2017 Nov 9:1-5; [Epub ahead of print]
Distinct Clinical, Laboratory, and Molecular Features of Myeloproliferative Neoplasm Patients with Splanchnic Vein Thrombosis.
How J, Trinkaus KM, Oh ST.
Br J Haematol. 2017 Oct 19. [Epub ahead of print].
NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018
Mesa RA, Jamieson C, Bhatia R, Deininger MW, Fletcher CD, Gerds AT, Gojo I, Gotlib J, Gundabolu K, Hobbs G, McMahon B, Mohan SR, Oh S, Padron E, Papadantonakis N, Pancari P, Podoltsev N, Rampal R, Ranheim E, Reddy V, Rein LAM, Scott B, Snyder DS, Stein BL, Talpaz M, Verstovsek S, Wadleigh M, Wang ES, Bergman MA, Gregory KM, Sundar H.
J Natl Compr Canc Netw 2017 Oct;15(10):1193-1207
Prognostication in Philadelphia Chromosome Negative Myeloproliferative Neoplasms: A review of the recent literature.
Zhou A, Afzal A, Oh ST.
Current Hematologic Malignancy Reports. 2017 Sep 25. [Epub ahead of print].
Analysis of Signaling Networks at the Single Cell Level Using Mass Cytometry.
Bandyopadhyay S, Fisher DA, Malkova O, Oh ST.
In Methods in Molecular Biology – Kinase Signaling Networks. Edited by Huang P, Tan, A-C. 2017;1636:371-392.
Cholesterol esterification inhibition and imatinib treatment synergistically inhibit growth of BCR-ABL mutation-independent resistant chronic myelogenous leukemia.
Bandyopadhyay S, Li J, Traer E, Tyner JW, Zhou A, Oh ST, Cheng J.
PLoS One. 2017 Jul 18;12(7):e0179558.
A phase 2 study of simtuzumab in patients with primary, post-polycythaemia vera or post-essential thrombocythaemia myelofibrosis
Verstovsek S, Savona MR, Mesa RA, Dong H, Maltzman JD, Sharma S, Silverman J, Oh ST, Gotlib J
Br J Haematol 2017 Mar;176(6):939-949
Splanchnic vein thrombosis in myeloproliferative neoplasms: pathophysiology and molecular mechanisms of disease.
How J, Zhou A, Oh ST.
Ther Adv Hematol 2017 Mar;8(3):107-118
Mass cytometry analysis reveals hyperactive NF Kappa B signaling in myelofibrosis and secondary acute myeloid leukemia.
Fisher DA, Malkova O, Engle EK, Miner CA, Fulbright MC, Behbehani GK, Collins TB, Bandyopadhyay S, Zhou A, Nolan GP, Oh ST.
Leukemia. 2017 Sep;31(9):1962-1974.
Myeloproliferative neoplasms, version 2.2017, NCCN clinical practice guidelines in oncology
Mesa R, Jamieson C, Bhatia R, Deininger MW, Gerds AT, Gojo I, Gotlib J, Gundabolu K, Hobbs G, Klisovic RB, Kropf P, Mohan SR, Oh S, Padron E, Podoltsev N, Pollyea DA, Rampal R, Rein LA, Scott B, Snyder DS, Stein BL, Verstovsek S, Wadleigh M, Wang ES, Bergman MA, Gregory KM, Sundar H
J Natl Compr Canc Netw 2016 Dec;14(12):1572-1611
Concurrent MPL W515L and Y591D mutations in a patient with myelofibrosis.
Rashidi A, Heusel JW, Oh ST.
Blood Cells, Molecules, and Diseases. 2016 Sep (60): 1-2.
Clinical Improvement with JAK2 Inhibition in Chuvash Polycythemia.
Zhou AW, Knoche EM, Engle EK, Ban-Hoefen M, Kaiwar C, Oh ST.
N Engl J Med. 2016 Aug 4; 376:494-496.
Concomitant JAK2 V617F-positive polycythemia vera and BCR-ABL-positive chronic myelogenous leukemia treated with ruxolitinib and dasatinib.
Zhou A, Knoche EM, Engle EK, Fisher DA, Oh ST
Blood Cancer J. 2015 Oct 2;5:e351.
Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617F.
Stein BL, Oh ST, Berenzon D, Hobbs GS, Kremyanskaya M, Rampal RK, Abboud CN, Adler K, Heaney ML, Jabbour EJ, Komrokji RS, Moliterno AR, Ritchie EK, Rice L, Mascarenhas J, Hoffman R.
J Clin Oncol. 2015 Aug 31. pii: JCO.2015.61.6474. [Epub ahead of print]
Clonal evolution revealed by whole genome sequencing in a case of primary myelofibrosis transformed to secondary acute myeloid leukemia.
Engle EK, Fisher DA, Miller CA, McLellan MD, Fulton RS, Moore DM, Wilson RK, Ley TJ, Oh ST
Leukemia. 2015 Apr;29(4):869-76.
Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms.
Stein BL, Gotlib J, Arcasoy M, Nguyen MH, Shah N, Moliterno A, Jamieson C, Pollyea DA, Scott B, Wadleigh M, Levine R, Komrokji R, Klisovic R, Gundabolu K, Kropf P, Wetzler M, Oh ST, Ribeiro R, Paschal R, Mohan S, Podoltsev N, Prchal J, Talpaz M, Snyder D, Verstovsek S, Mesa RA.
J Natl Compr Canc Netw. 2015 Apr;13(4):424-34.
Prognostication in MF: From CBC to Cytogenetics to Molecular Markers.
Zhou A, Oh ST
Best Pract Res Clin Haematol. 2014 Jun;27(2):155-164.
Disseminated tuberculosis associated with ruxolitinib
Hopman RK, Lawrence SJ, Oh ST
Leukemia 2014 Aug;28(8):1750-1
Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML
Maxson JE, Gotlib J, Pollyea DA, Fleischman AG, Agarwal A, Eide CA, Bottomly D, Wilmot B, McWeeney SK, Tognon CE, Pond JB, Collins RH, Goueli B, Oh ST, Deininger MW, Chang BH, Loriaux MM, Druker BJ, Tyner JW
N Engl J Med 2013 May 9;368(19):1781-90
Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening
Tyner JW, Yang WF, Bankhead A 3rd, Fan G, Fletcher LB, Bryant J, Glover JM, Chang BH, Spurgeon SE, Fleming WH, Kovacsovics T, Gotlib JR, Oh ST, Deininger MW, Zwaan CM, Den Boer ML, van den Heuvel-Eibrink MM, O'Hare T, Druker BJ, Loriaux MM
Cancer Res 2013 Jan 1;73(1):285-296
Pathology consultation on myeloproliferative neoplasms
Schmidt AE, Oh ST
Am J Clin Pathol 2012 Jul;138(1):12-19
A novel splice donor mutation in the thrombopoietin gene leads to exon 2 skipping in a Filipino family with hereditary thrombocythemia
Zhang B, Ng D, Jones C, Oh ST, Nolan GP, Salehi S, Wong W, Zehnder JL, Gotlib J
Blood 2011 Dec 22;118(26):6988-90
When the brakes are lost: LNK dysfunction in mice, men, and myeloproliferative neoplasms
Oh ST
Therapeutic Advances in Hematology 2011;2:11-19
LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations
Pardanani A, Lasho T, Finke C, Oh ST, Gotlib J, Tefferi A
Leukemia 2010 Oct;24(10):1713-8
Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms
Oh ST, Simonds EF, Jones C, Hale MB, Goltsev Y, Gibbs KD Jr, Merker JD, Zehnder JL, Nolan GP, Gotlib J
Blood 2010 Aug 12;116(6):988-92
JAK2 V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms
Oh ST, Gotlib J
Expert Rev Hematol 2010 Jun;3(3):323-37
Design and evaluation of a real-time PCR assay for quantification of JAK2 V617F and wild-type JAK2 transcript levels in the clinical laboratory
Merker JD, Jones CD, Oh ST, Schrijver I, Gotlib J, Zehnder JL
J Mol Diagn 2010 Jan;12(1):58-64
Antiangiogenic therapy in myelodysplastic syndromes: is there a role?
Oh ST, Gotlib J
Curr Hematol Malig Rep 2008 Jan;3(1):10-8
Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement
Strati P, Tang G, Duose DY, Mallampati S, Luthra R, Patel KP, Hussaini M, Mirza AS, Komrokji RS, Oh S, Mascarenhas J, Najfeld V, Subbiah V, Kantarjian H, Garcia-Manero G, Verstovsek S, Daver N
Leuk Lymphoma 2017 Nov 9:1-5; [Epub ahead of print]
Distinct Clinical, Laboratory, and Molecular Features of Myeloproliferative Neoplasm Patients with Splanchnic Vein Thrombosis.
How J, Trinkaus KM, Oh ST.
Br J Haematol. 2017 Oct 19. [Epub ahead of print].
NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018
Mesa RA, Jamieson C, Bhatia R, Deininger MW, Fletcher CD, Gerds AT, Gojo I, Gotlib J, Gundabolu K, Hobbs G, McMahon B, Mohan SR, Oh S, Padron E, Papadantonakis N, Pancari P, Podoltsev N, Rampal R, Ranheim E, Reddy V, Rein LAM, Scott B, Snyder DS, Stein BL, Talpaz M, Verstovsek S, Wadleigh M, Wang ES, Bergman MA, Gregory KM, Sundar H.
J Natl Compr Canc Netw 2017 Oct;15(10):1193-1207
Prognostication in Philadelphia Chromosome Negative Myeloproliferative Neoplasms: A review of the recent literature.
Zhou A, Afzal A, Oh ST.
Current Hematologic Malignancy Reports. 2017 Sep 25. [Epub ahead of print].
Analysis of Signaling Networks at the Single Cell Level Using Mass Cytometry.
Bandyopadhyay S, Fisher DA, Malkova O, Oh ST.
In Methods in Molecular Biology – Kinase Signaling Networks. Edited by Huang P, Tan, A-C. 2017;1636:371-392.
Cholesterol esterification inhibition and imatinib treatment synergistically inhibit growth of BCR-ABL mutation-independent resistant chronic myelogenous leukemia.
Bandyopadhyay S, Li J, Traer E, Tyner JW, Zhou A, Oh ST, Cheng J.
PLoS One. 2017 Jul 18;12(7):e0179558.
A phase 2 study of simtuzumab in patients with primary, post-polycythaemia vera or post-essential thrombocythaemia myelofibrosis
Verstovsek S, Savona MR, Mesa RA, Dong H, Maltzman JD, Sharma S, Silverman J, Oh ST, Gotlib J
Br J Haematol 2017 Mar;176(6):939-949
Splanchnic vein thrombosis in myeloproliferative neoplasms: pathophysiology and molecular mechanisms of disease.
How J, Zhou A, Oh ST.
Ther Adv Hematol 2017 Mar;8(3):107-118
Mass cytometry analysis reveals hyperactive NF Kappa B signaling in myelofibrosis and secondary acute myeloid leukemia.
Fisher DA, Malkova O, Engle EK, Miner CA, Fulbright MC, Behbehani GK, Collins TB, Bandyopadhyay S, Zhou A, Nolan GP, Oh ST.
Leukemia. 2017 Sep;31(9):1962-1974.
Myeloproliferative neoplasms, version 2.2017, NCCN clinical practice guidelines in oncology
Mesa R, Jamieson C, Bhatia R, Deininger MW, Gerds AT, Gojo I, Gotlib J, Gundabolu K, Hobbs G, Klisovic RB, Kropf P, Mohan SR, Oh S, Padron E, Podoltsev N, Pollyea DA, Rampal R, Rein LA, Scott B, Snyder DS, Stein BL, Verstovsek S, Wadleigh M, Wang ES, Bergman MA, Gregory KM, Sundar H
J Natl Compr Canc Netw 2016 Dec;14(12):1572-1611
Concurrent MPL W515L and Y591D mutations in a patient with myelofibrosis.
Rashidi A, Heusel JW, Oh ST.
Blood Cells, Molecules, and Diseases. 2016 Sep (60): 1-2.
Clinical Improvement with JAK2 Inhibition in Chuvash Polycythemia.
Zhou AW, Knoche EM, Engle EK, Ban-Hoefen M, Kaiwar C, Oh ST.
N Engl J Med. 2016 Aug 4; 376:494-496.
Concomitant JAK2 V617F-positive polycythemia vera and BCR-ABL-positive chronic myelogenous leukemia treated with ruxolitinib and dasatinib.
Zhou A, Knoche EM, Engle EK, Fisher DA, Oh ST
Blood Cancer J. 2015 Oct 2;5:e351.
Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617F.
Stein BL, Oh ST, Berenzon D, Hobbs GS, Kremyanskaya M, Rampal RK, Abboud CN, Adler K, Heaney ML, Jabbour EJ, Komrokji RS, Moliterno AR, Ritchie EK, Rice L, Mascarenhas J, Hoffman R.
J Clin Oncol. 2015 Aug 31. pii: JCO.2015.61.6474. [Epub ahead of print]
Clonal evolution revealed by whole genome sequencing in a case of primary myelofibrosis transformed to secondary acute myeloid leukemia.
Engle EK, Fisher DA, Miller CA, McLellan MD, Fulton RS, Moore DM, Wilson RK, Ley TJ, Oh ST
Leukemia. 2015 Apr;29(4):869-76.
Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms.
Stein BL, Gotlib J, Arcasoy M, Nguyen MH, Shah N, Moliterno A, Jamieson C, Pollyea DA, Scott B, Wadleigh M, Levine R, Komrokji R, Klisovic R, Gundabolu K, Kropf P, Wetzler M, Oh ST, Ribeiro R, Paschal R, Mohan S, Podoltsev N, Prchal J, Talpaz M, Snyder D, Verstovsek S, Mesa RA.
J Natl Compr Canc Netw. 2015 Apr;13(4):424-34.
Prognostication in MF: From CBC to Cytogenetics to Molecular Markers.
Zhou A, Oh ST
Best Pract Res Clin Haematol. 2014 Jun;27(2):155-164.
Disseminated tuberculosis associated with ruxolitinib
Hopman RK, Lawrence SJ, Oh ST
Leukemia 2014 Aug;28(8):1750-1
Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML
Maxson JE, Gotlib J, Pollyea DA, Fleischman AG, Agarwal A, Eide CA, Bottomly D, Wilmot B, McWeeney SK, Tognon CE, Pond JB, Collins RH, Goueli B, Oh ST, Deininger MW, Chang BH, Loriaux MM, Druker BJ, Tyner JW
N Engl J Med 2013 May 9;368(19):1781-90
Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening
Tyner JW, Yang WF, Bankhead A 3rd, Fan G, Fletcher LB, Bryant J, Glover JM, Chang BH, Spurgeon SE, Fleming WH, Kovacsovics T, Gotlib JR, Oh ST, Deininger MW, Zwaan CM, Den Boer ML, van den Heuvel-Eibrink MM, O'Hare T, Druker BJ, Loriaux MM
Cancer Res 2013 Jan 1;73(1):285-296
Pathology consultation on myeloproliferative neoplasms
Schmidt AE, Oh ST
Am J Clin Pathol 2012 Jul;138(1):12-19
A novel splice donor mutation in the thrombopoietin gene leads to exon 2 skipping in a Filipino family with hereditary thrombocythemia
Zhang B, Ng D, Jones C, Oh ST, Nolan GP, Salehi S, Wong W, Zehnder JL, Gotlib J
Blood 2011 Dec 22;118(26):6988-90
When the brakes are lost: LNK dysfunction in mice, men, and myeloproliferative neoplasms
Oh ST
Therapeutic Advances in Hematology 2011;2:11-19
LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations
Pardanani A, Lasho T, Finke C, Oh ST, Gotlib J, Tefferi A
Leukemia 2010 Oct;24(10):1713-8
Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms
Oh ST, Simonds EF, Jones C, Hale MB, Goltsev Y, Gibbs KD Jr, Merker JD, Zehnder JL, Nolan GP, Gotlib J
Blood 2010 Aug 12;116(6):988-92
JAK2 V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms
Oh ST, Gotlib J
Expert Rev Hematol 2010 Jun;3(3):323-37
Design and evaluation of a real-time PCR assay for quantification of JAK2 V617F and wild-type JAK2 transcript levels in the clinical laboratory
Merker JD, Jones CD, Oh ST, Schrijver I, Gotlib J, Zehnder JL
J Mol Diagn 2010 Jan;12(1):58-64
Antiangiogenic therapy in myelodysplastic syndromes: is there a role?
Oh ST, Gotlib J
Curr Hematol Malig Rep 2008 Jan;3(1):10-8
